You are here: Home » Markets » News
Business Standard

Granules India rallies 8% in a weak market, hits fresh all-time high

The stock hit a record high of Rs 350 today. It has surged 13% thus far in the current week, as compared to a 2% decline in the S&P BSE Sensex

Topics
Granules India | Buzzing stocks | Markets

SI Reporter  |  Mumbai 

On August 22, Granules India had announced that its subsidiary company Granules Pharmaceuticals Inc had received approval from
On August 22,Granule India's subsidiary company Granules Pharmaceuticals Inc had received approval from US FDA for Ramelteon Tablets

Shares of hit an all-time high of Rs 350 in an otherwise weak market, ralling 8 per cent on the BSE on Friday. Thus far in the current week, the stock of the pharmaceutical company has surged 13 per cent as compared to 2 per cent decline in the S&P BSE Sensex. It surpassed its previous high of Rs 336 touched on August 10, 2020.

On August 22, had announced that its subsidiary company Granules Pharmaceuticals Inc had received approval from the US Food & Drug Administration (US FDA) for Ramelteon Tablets 8 mg, a bioequivalent to the reference listed drug product (RLD), Rozerem Tablets, 8 mg, of Takeda Pharmaceuticals USA.

"Ramelteon Tablets are used for the treatment of insomnia characterised by difficulty with sleep onset. Ramelteon Tablets had US sales of approximately $33 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health," it said. READ HERE

For April-June (Q1FY21) quarter, had reported robust earning with quarterly revenue of Rs 736 crore and an EBITDA (earnings before interest, taxes, depreciation, and amortization) margin of 25 per cent, up 503 bps from Q1FY20.

Major growth contribution was due to a significant increase in production to cater to new product launches and increase in market share of existing products across the three verticals, the company said.

According to analysts, its dominance in key APIs (paracetamol, ibuprofen, metformin) would help Granules emerge aa a prime beneficiary as Covid-19 outbreak has led to a surge in demand for such drugs. Granules, they say, is likely to retain strong traction for the next couple of years driven by formulations and the healthy contribution from new capacities.

At 02:22 pm, the stock was trading 6 per cent higher at Rs 344 on the BSE, as against 1 per cent decline in the S&P BSE Sensex. The trading volumes on the counter jumped 1.7 times as combined 6.8 million shares had changed hands on the NSE and BSE till the time of writing of this report.

First Published: Fri, September 04 2020. 14:25 IST
RECOMMENDED FOR YOU